Sakura Bio

Sakura Bio has developed an off-the-shelf, naïve PBMC-derived allogeneic T-cell therapy to fight cancer — in particular, acute myeloid leukemia. The company's platform focuses on creating super-activated killer cells, an allogenic T-cell therapy produced via a simple, relatively short manipulation of naïve PBMCs. Sakura Bio's lead product, Super Activated Killer T-cell (SAK-T), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. In contrast to other T-cell-based products, such as CAR-T, SAK-T cells have a high safety profile, with no graft-versus-host disease, and can be developed as an off-the-shelf T-cell product. SAK-T's outstanding killing properties of leukemic cells led Sakura to choose acute myeloid leukemia as its first-in-human indication for SAK therapy.

Sakura Bio has raised $1.7M in total funding across 1 rounds. The company is currently at the Pre-Seed stage. Key investors include VLX Ventures.

Sakura Bio was founded in 2022 by Dikla Berko-Ashur (Co-Founder & CEO).

Sakura Bio operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells. Target customers: Healthcare & Life Sciences, Healthcare, Laboratories.

Sakura Bio is based in Jerusalem, Israel.